Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease.
“Until enough people are vaccinated to achieve global herd immunity in the face of waves of emerging mutant strains of the virus, millions of people are likely to continue to suffer severe COVID-19 disease involving major disabilities and death,” said Noxopharm CEO Graham Kelly. “That is where we see Veyonda playing a key role, with its STING blocking action stopping the destructive inflammatory process in patients with moderate COVID-19. The interim data released today points to Veyonda delivering on this promise.”
The major challenge for hospital services during the current pandemic is the high level of care required for those patients experiencing rapid deterioration of lung function, leading to acute respiratory distress syndrome, septic shock, and major disabilities or death. A key factor associated with disease worsening is the excessive production of inflammatory factors normally invoked to facilitate tissue repair and combat infection in a process known as the cytokine storm.
Biomarker data from the top Veyonda dose cohort is expected within the next few weeks. That will be followed by a review of the final clinical data on completion of treatment of the final patient. Clinical status (WHO COVID-19 grade, comorbidities) and other therapies will be considered, and after reviewing all the data, the Company will then consult with government, regulatory, medical, and business development advisors.
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock. Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialing. Veyonda has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signaling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ADVA adds encryption to flagship 10G edge device11.5.2021 09:00:00 CEST | Press release
ADVA (FSE: ADV) today launched its FSP 150-XG118Pro (CSH), addressing urgent enterprise demand for high-bandwidth connectivity with robust security. The new member of the ADVA FSP 150 programmable demarcation and edge compute portfolio supports 10Gbit/s MEF 3.0 Carrier Ethernet and IP services, provides precise synchronization capabilities and now features hardware-based encryption. With its comprehensive MACsec security, the ADVA FSP 150-XG118Pro (CSH) enables business data to pass safely and seamlessly across untrusted public networks and empowers communication service providers (CSPs) to offer fully encrypted bandwidth services. What’s more, like ADVA’s FSP 3000 transport solution, the ADVA FSP 150-XG118Pro (CSH) is ready to run post-quantum cryptographic (PQC) algorithms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005059/en/ ADVA’s new FSP 150 will prove key for businesses seeking ultimate security for high-cap
21st BraunPrize Seeks to Reward Good Design That Will Shape Tomorrow11.5.2021 09:00:00 CEST | Press release
Braun celebrates its 100th anniversary in 2021 and we are pleased to announce the 21st BraunPrize International Design Competition, with a virtual awards ceremony due to take place in October 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005118/en/ Established in 1968, the BraunPrize was Germany’s first international competition with the aim to promote the work of young designers. Braun’s continuous commitment to this cause has been highly regarded by the design world and the design-aware public ever since. This year, young, up-and-coming designers and inventors will be tasked with exploring good design to address and solve the challenges of today and tomorrow; and Braun’s commitment to nurturing young talent will see this year’s total prize value increase to $100,000 USD. A recent global study, conducted by Braun of 18-25 year olds, revealed that Gen Z believes that good design will play a pivotal role in its f
Galderma Launches CETAPHIL® Line for Sensitive Skin and New DAYLONG® Sun Protection Product in Switzerland11.5.2021 09:00:00 CEST | Press release
Galderma has expanded its consumer care portfolio in Switzerland, where the global dermatology company originated and is headquartered. The expansion offers consumers more options for their dermatology needs. The move includes the introduction of the dermatologist-recommended CETAPHIL® line for sensitive skin, as well as the expansion of the DAYLONG® brand for sun protection. CETAPHIL is now available in Switzerland CETAPHIL, the sensitive skincare line recommended by dermatologists worldwide, is now available in Switzerland, exclusively in pharmacies and drugstores. The entry of the CETAPHIL range into the dermo-cosmetic market means consumers now have more choice of topical skincare for sensitive skin. Swiss consumers can now purchase the core range of CETAPHIL moisturizing creams, moisturizing lotion and gentle skin cleanser. Additionally, the CETAPHIL PRO range for special skin conditions completes the CETAPHIL portfolio. The brand enters the dermo-cosmetic market as a complementar
Curve Launches New Crowdfund to Bring Customers Closer to its Growth Journey11.5.2021 09:00:00 CEST | Press release
Curve, the fast-growing financial super app, today announces it’s launching a new crowdfunding round to enable its growing customer base to invest, as it fuels its expansion into the US and further into Europe. The campaign is set to go live sometime in May. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005170/en/ Curve Launches New Crowdfund to Bring Customers Closer to its Growth Journey (Graphic: Business Wire) Having secured £72.5 million from a leading group of international investors as part of its successful Series C round, Curve is now extending the opportunity to its customers and wider community to take part in the next stage of its ambitious growth strategy. Since its record-breaking crowdfund in 2019, which raised £4 million within 42 minutes, Curve’s valuation has tripled. In the last year alone, Curve hired over 100 new staff, doubled its customer base to over two million, and saw the volume of transacti
Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY202111.5.2021 08:35:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021). TAKEDA PRESIDENT AND CHIEF EXECUTIVE OFFICER CHRISTOPHE WEBER commented: “Over the course of FY2020, Takeda remained resilient as we operated in new ways through the COVID-19 pandemic. This is a testament to the dedication of our employees, and Takeda’s unwavering commitment to serving patients, our people, and the planet to bring better health for people and a brighter future for the world. We maintained business continuity, ensured patient access to our medicines and safeguarded the health and well-being of our employees while helping to address the pandemic. “This focus enabled us to deliver on our full-year management guidance, with underlying revenue growth driven by our 14 global brands, and the acceleration of cost synergies contributed to strong margins and a robust cashflow. Furthermore, we continued to experience growth
EMG Announces Appointment of Shaun Gregory as New Group Chief Executive Officer11.5.2021 08:30:00 CEST | Press release
EMG, a leading global provider of broadcast facilities and media solutions, announced today that Shaun Gregory will join the company as Group Chief Executive Officer starting May 17th 2021. Gregory is a seasoned executive with over 30 years of experience in the media, telecommunications & broadcasting industries. He has served as Chief Executive Officer for some of the fastest growing companies, both in Europe and globally. Under his leadership, EMG will continue the development of its ambitious transformation strategy. He will succeed co-CEO Patrick van den Berg who after 15 years serving in various leadership positions at EMG will take on a new professional challenge while co-CEO François-Charles Bideaux will become advisor to the CEO & EMG board focusing on specific areas such as sales, technology and M&A. Most recently, Gregory was CEO of media localization company IYUNO Media Group (formerly BTI Studios) which spans 46 countries and 88 language types, servicing the world’s leading
Altium Announces Cloud Platform To Connect Electronics Industry Ecosystem11.5.2021 08:30:00 CEST | Press release
Altium LLC is announcing the launch of Nexar, the cloud-based partner platform designed to connect the rapidly growing community of Altium 365 PCB design users and their companies with the software, suppliers, and manufacturers needed to transform ideas into smart & connected products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510006069/en/ Electronics industry researchers estimate that there are 31 billion internet-connected devices in the world today, with consumer demand growing that number to 75 billion by 2025. Growth of that magnitude is driving the need to reimagine the way that the electronics industry works together, evolving from “tool chains” and isolated job functions to integrated environments and collaborative workflows. Over 5,000 companies and 11,000 users have already adopted the Altium 365 cloud platform for electronics design. With the introduction of Nexar, partners can join this ecosystem of elec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom